- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04817046
Assessment of Early-detection Based on Liquid Biopsy in Lung Cancer (ASCEND-LUNG)
March 24, 2021 updated by: Jun Wang, Peking University People's Hospital
Detection of Early-stage Lung Cancer Based on Liquid Biopsy of Peripheral Blood: a Prospective Study
The purpose of this study is to develop a lung cancer diagnosis tool using a multi-omics approach based on liquid biopsy.
Study Overview
Status
Recruiting
Conditions
Detailed Description
After being informed about the study and potential risks, all patients giving written informed consent will undergo a screening process to determine eligibility of study entry.
Peripheral blood, tissue sample and imaging examinations of eligible patients will be collected for further analysis.
Data collected will be used to develop a multi-omics lung cancer diagnosis model.
Study Type
Observational
Enrollment (Anticipated)
467
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Kezhong Chen, MD
- Phone Number: 08601088326650
- Email: chenkezhong@pkuph.edu.cn
Study Contact Backup
- Name: Fan Yang, MD
- Phone Number: 08601088326650
- Email: yangfan@pkuph.edu.cn
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100044
- Recruiting
- Peking University People's Hospital
-
Contact:
- Chen Kezhong, M.D.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 74 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Newly diagnosed lung cancer patients between 40-75 years old, with solid nodule on CT imaging.
Description
Inclusion Criteria:
- Signed informed consent
- Male or female, age equal to or greater than 40 years old and less than 75 years old
- Blood sample was collected before surgery for the detection of cfDNA methylation and other biomarkers
- Lung cancer patients diagnosed for the first time within 42 days before blood sampling without any anti-tumor treatment; or patients who are highly suspected of lung cancer through imaging evaluation or other routine clinical diagnosis and confirmed by tissue biopsy or surgical specimens within 42 days after blood sampling
- The subject has not received any local or systemic anti-tumor therapy before blood collection, including (not limited to) any surgery, local or systemic radiotherapy and chemotherapy, targeted therapy (including anti-angiogenesis), immunotherapy, cancer vaccines and hormone therapy, etc.
Exclusion Criteria:
- Unable to obtain sufficient and qualified blood samples
- Female subjects who are pregnant or breastfeeding
- Patients who have received organ transplantation or non-autologous bone marrow or stem cell transplantation
- Patients who have received blood transfusion within 7 days before blood sampling
- Patients who have received anti-infection treatment within 14 days before blood collection
- Patients who have receiving anti-tumor drugs for other diseases within 30 days before blood collection, such as methotrexate, cyclophosphamide, mercaptopurine, chlorambucil, tamoxifen, etc.
- Patients who suffered from other malignant tumors or multiple primary tumors at the same time
- Pathological confirmed benign lesions by tissue biopsy or surgery
- Insufficient sample for a confirmed pathological diagnosis
- Lung cancer patients with ground glass nodules on CT imaging.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Accuracy of the multi-omics early-stage lung cancer diagnosis model
Time Frame: through study completion, an average of 1.5 year
|
Sensitivity and specificity of the multi-omics early-stage lung cancer diagnosis model
|
through study completion, an average of 1.5 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Accuracy of diagnostic models established separately from multi-omics data
Time Frame: through study completion, an average of 1.5 year
|
Sensitivity and specificity models established separately from multi-omics data
|
through study completion, an average of 1.5 year
|
|
Relationship between multi-omics data
Time Frame: through study completion, an average of 1.5 year
|
Explore the relationship of features extracted from multi-omics data
|
through study completion, an average of 1.5 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Fan Yang, MD, Peking University People's Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 19, 2021
Primary Completion (Anticipated)
December 31, 2022
Study Completion (Anticipated)
December 31, 2024
Study Registration Dates
First Submitted
March 10, 2021
First Submitted That Met QC Criteria
March 24, 2021
First Posted (Actual)
March 25, 2021
Study Record Updates
Last Update Posted (Actual)
March 25, 2021
Last Update Submitted That Met QC Criteria
March 24, 2021
Last Verified
March 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PTHO2101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.